CellCure Neurosciences Ltd
Sub-category: Tissue Engineering & Cell Therapy
Medical field: Ophthalmology
Cell Cure Neurosciences Ltd. (Cell Cure) is focused on the development of cell therapies for retinal and neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. Both of these cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company's OpRegen® product is intended for use in RPE transplantations in patients with age related macular degeneration (AMD) and is expected to be among the first hESC based products to reach clinical trials.
|Charles Irving, CEO|
|Cellcure Neurosciences Ltd, POB 12247 Jerusalem 91121|
To update your company data, click here.